Search
Colorado Paid Clinical Trials
A listing of 1810 clinical trials in Colorado actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1345 - 1356 of 1810
Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
COVID-19 Vaccine Clinical Trial (Compensation Provided)
Recruiting
Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.
Qualified participants may receive compensation for time and travel.
Qualified participants may receive compensation for time and travel.
Conditions:
Healthy
Vaccine
COVID19
COVID-19
COVID-19 Vaccine
Featured Trial
Type 2 Diabetes (T2DM) Clinical Study
Recruiting
A clinical study for people that suffer with Type 2 Diabetes (T2DM)
Conditions:
Type 2 Diabetes (T2DM)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion
Recruiting
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given.
The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/14/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Timing Intervention of Morning Versus Evening Exercise
Recruiting
The investigators are doing this study to learn more about how exercising at different times of the day (morning versus evening) affects body weight, sleep, eating patterns, and other factors.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/13/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Overweight and Obesity
Clinical Outcomes Study of the Nexel Total Elbow
Recruiting
The objectives of the study are to confirm safety and performance of the Zimmer Nexel Total Elbow when used in primary or revision total elbow replacement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Panorama Orthopedics and Spine Center, Golden, Colorado
Conditions: Elbow Joint Destruction, Post-traumatic Lesions, Ankylosed Joints, Advanced Rheumatoid Arthritis, Joint Instability or Loss of Motion, Acute Comminuted Articular Fracture of Elbow Joint Surfaces, Bone Loss Contributing to Elbow Instability, Bilateral Ankylosis From Causes Other Than Active Sepsis, Post-traumatic Arthritis, Degenerative Arthritis
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Recruiting
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D).
P... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/12/2025
Locations: Children's Hospital Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Maestro 1.1 Post-Market Registry
Recruiting
The objective of the study is to observe the real-life usage of the Maestro Platform for surgical assistance in laparoscopic surgery.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/11/2025
Locations: Rose Medical Center, Denver, Colorado
Conditions: Surgery
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Recruiting
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Solid Tumor, Adult, Refractory Cancer, Cutaneous Melanoma, Non-small Cell Lung Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum
Omega Cuff for GERD Feasibility Study
Recruiting
This clinical feasibility study is to evaluate the performance of the Omega-Cuff in the treatment of acid reflux for up to 15 patients with a 1-year follow-up period. The Omega-shaped nitinol device is placed on top of the esophageal sphincter muscle just above the stomach in a laparoscopic surgical procedure without altering anatomy. In animal studies, the device safely increased the pressure on the sphincter, meaning it increased resistance to acid reflux, but did not interfere with normal foo... Read More
Gender:
ALL
Ages:
Between 22 years and 74 years
Trial Updated:
02/11/2025
Locations: SOFI Research/Foregut Research Foundation, Lone Tree, Colorado
Conditions: GERD, Acid Reflux, Treatment
Freedom-1 Study for Chronic Knee Pain
Recruiting
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Colorado Pain Care, LLC, Denver, Colorado
Conditions: Osteoarthritic Knee Pain
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Recruiting
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
02/10/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Surgical or Medical Treatment
Recruiting
This study will test the hypothesis that metabolic bariatric surgery will be more effective at providing durable glycemic control and reduce co-morbidities than intensive medical therapy in youth with type 2 diabetes.
Gender:
ALL
Ages:
Between 13 years and 19 years
Trial Updated:
02/10/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Diabetes Mellitus, Type 2, Pediatric Obesity, Bariatric Surgery Candidate
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Recruiting
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Rocky Mountain Cancer Centers, Aurora, Colorado
Conditions: Higher-risk Myelodysplastic Syndromes
